In the preceding three months, 6 analysts have released ratings for NewAmsterdam Pharma (NASDAQ:NAMS), presenting a wide array of perspectives from bullish to bearish.

Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.

In the assessment of 12-month price targets, analysts unveil insights for NewAmsterdam Pharma, presenting an average target of $39.83, a high estimate of $48.00, and a low estimate of $36.00. Observing a 11.26% increase, the current average has risen from the previous average price target of $35.80.

Understanding Analyst Ratings: A Comprehensive Breakdown

A clear picture of NewAmsterdam Pharma's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.

Key Insights:

Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of NewAmsterdam Pharma's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.

Stay up to date on NewAmsterdam Pharma analyst ratings.

Discovering NewAmsterdam Pharma: A Closer Look

NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.

A Deep Dive into NewAmsterdam Pharma's Financials

Market Capitalization Analysis: Above industry benchmarks, the company's market capitalization emphasizes a noteworthy size, indicative of a strong market presence.

Revenue Growth: Over the 3 months period, NewAmsterdam Pharma showcased positive performance, achieving a revenue growth rate of 889.83% as of 30 September, 2024. This reflects a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.

Net Margin: NewAmsterdam Pharma's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -57.18% net margin, the company effectively manages costs and achieves strong profitability.

Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of -4.34%, the company showcases effective utilization of equity capital.

Return on Assets (ROA): NewAmsterdam Pharma's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of -3.76%, the company showcases efficient use of assets and strong financial health.

Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.0.

What Are Analyst Ratings?

Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.

Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.

Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.

Breaking: Wall Street's Next Big Mover

Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. Click here for urgent details.

This article was generated by Benzinga's automated content engine and reviewed by an editor.